Riess J, Lara M, Lopez de Rodas M, Luxardi G, Herbert S, Shimoda M
JTO Clin Res Rep. 2024; 5(10):100706.
PMID: 39318388
PMC: 11420451.
DOI: 10.1016/j.jtocrr.2024.100706.
Yuan Y, Mishra F, Li B, Peng G, Chan P, Yang J
Cancers (Basel). 2024; 16(13).
PMID: 39001545
PMC: 11240634.
DOI: 10.3390/cancers16132483.
Parmar A, Lu B, Luo J, Chan K
Future Oncol. 2024; 20(36):2879-2888.
PMID: 38861308
PMC: 11572188.
DOI: 10.1080/14796694.2024.2342224.
Lim R, Salehi-Rad R, Tran L, Oh M, Dumitras C, Crosson W
Cell Rep Med. 2024; 5(4):101479.
PMID: 38518770
PMC: 11031384.
DOI: 10.1016/j.xcrm.2024.101479.
Piggott L, Hayes C, Greene J, Fitzgerald D
Breathe (Sheff). 2024; 19(4):230145.
PMID: 38351947
PMC: 10862126.
DOI: 10.1183/20734735.0145-2023.
Phosphorylation of AGO2 by TBK1 Promotes the Formation of Oncogenic miRISC in NSCLC.
Zhao X, Cao Y, Lu R, Zhou Z, Huang C, Li L
Adv Sci (Weinh). 2024; 11(15):e2305541.
PMID: 38351659
PMC: 11022703.
DOI: 10.1002/advs.202305541.
Referred molecular testing as a barrier to optimal treatment decision making in metastatic non-small cell lung cancer: Experience at a tertiary academic institution in Canada.
Grafham G, Craddock K, Huang W, Louie A, Zhang L, Hwang D
Cancer Med. 2024; 13(3):e6886.
PMID: 38317584
PMC: 10905241.
DOI: 10.1002/cam4.6886.
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.
Mok T, Nakagawa K, Park K, Ohe Y, Girard N, Kim H
J Clin Oncol. 2024; 42(11):1252-1264.
PMID: 38252907
PMC: 11095864.
DOI: 10.1200/JCO.23.01017.
The efficacy and safety of immune checkpoint inhibitors for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy: A systematic review and network meta-analysis.
Wang Z, Zhou F, Xu S, Wang K, Ding H
Cancer Med. 2023; 12(18):18516-18530.
PMID: 37584242
PMC: 10557893.
DOI: 10.1002/cam4.6453.
Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics.
Padinharayil H, Varghese J, John M, Rajanikant G, Wilson C, Al-Yozbaki M
Genes Dis. 2023; 10(3):960-989.
PMID: 37396553
PMC: 10308181.
DOI: 10.1016/j.gendis.2022.07.023.
Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: State-of-the-Art Review.
Tan S, Day D, Nicholls S, Segelov E
JACC CardioOncol. 2023; 4(5):579-597.
PMID: 36636451
PMC: 9830229.
DOI: 10.1016/j.jaccao.2022.09.004.
Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects.
Lievense L, Heukels P, van Walree N, van der Leest C
JTO Clin Res Rep. 2022; 4(1):100441.
PMID: 36578272
PMC: 9791802.
DOI: 10.1016/j.jtocrr.2022.100441.
Clinical Outcomes in COVID-19 Patients Treated with Immunotherapy.
Hatic H, Hearld K, Das D, Deshane J
Cancers (Basel). 2022; 14(23).
PMID: 36497435
PMC: 9735726.
DOI: 10.3390/cancers14235954.
Emerging role of chemokines in small cell lung cancer: Road signs for metastasis, heterogeneity, and immune response.
Khan P, Fatima M, Khan M, Batra S, Nasser M
Semin Cancer Biol. 2022; 87:117-126.
PMID: 36371025
PMC: 10199458.
DOI: 10.1016/j.semcancer.2022.11.005.
Live Biotherapeutic GEN3013 Enhances Antitumor Efficacy of Cancer Treatment via Modulation of Cancer Progression and Immune System.
Kim S, Kim Y, Lee S, Kim Y, Jeon B, Kim H
Cancers (Basel). 2022; 14(17).
PMID: 36077619
PMC: 9455052.
DOI: 10.3390/cancers14174083.
Solving the puzzle of what makes immunotherapies work.
Ma X, Chan T
Trends Cancer. 2022; 8(11):890-900.
PMID: 35933298
PMC: 10109520.
DOI: 10.1016/j.trecan.2022.06.011.
Endocrine and Neuroendocrine Tumors Special Issue-Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?.
Jimenez C, Armaiz-Pena G, Dahia P, Lu Y, Toledo R, Varghese J
Cancers (Basel). 2022; 14(3).
PMID: 35158739
PMC: 8833823.
DOI: 10.3390/cancers14030467.
Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells.
Goff P, Riolobos L, LaFleur B, Spraker M, Seo Y, Smythe K
Clin Cancer Res. 2022; 28(8):1701-1711.
PMID: 35115306
PMC: 9953754.
DOI: 10.1158/1078-0432.CCR-21-4239.
Advances in Immunotherapies for Gliomas.
Zhang M, Choi J, Lim M
Curr Neurol Neurosci Rep. 2022; 22(1):1-10.
PMID: 35107784
PMC: 9186001.
DOI: 10.1007/s11910-022-01176-9.
Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer.
Inoue H, Tsutsumi H, Tanaka K, Iwama E, Shiraishi Y, Hirayama A
Transl Lung Cancer Res. 2021; 10(6):2475-2486.
PMID: 34295655
PMC: 8264341.
DOI: 10.21037/tlcr-21-92.
